Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock face investor scrutiny as RFK Jr. takes the leadership of HHS. Read more ...
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.
Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...
The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...
A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.
Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
4d
Hosted on MSNHims & Hers Super Bowl controversy: What the ad left out about its 'alternative' weight-loss drugsThe telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results